2009•国际外科学杂志Requires access
Progress of neoadjuvant chemotherapy for pancreatic cancer
Peng Gong, Zhongyu Wang
Open publisher page 0 citations
Abstract
Surgical treatment has improved the prognosis of resectable pancreatic cancer considerably de-spite the generally aggressive behavior of its malignancy. Neoadjuvant therapy for pancreatic cancer has been shown effective in improving a survival benefit. Few prospective randomized controlled clinical trials (RCTs) on the use of neoadjuvant chemotherapy and chemoradiation has been done tp show the survival advantage of systemic chemotherapy (5-FU/FA or gemcitabine) following surgical resection. Up to now, there is no high-level evidence of any benefit deriving from neoadjuvant chemo therapy for pancreatic cancer. Well designed trials are needed to compare neoadjuvant chemotherapy with surgery to judge the value of neoadjuvant cherqo-therapy in multimodal treatment concepts of pancreatic cancer.
Key words:
pancreatic cancer; neoadjuvant chemotherapy